#Germany #Düsseldorf #Monoclonal Antibodies #LenioBio #mAIbe

mAIbe and LenioBio: A Strategic Collaboration

mAIbe, a biotechnology company specializing in artificial intelligence-driven monoclonal antibody design, and LenioBio, known for its pioneering platform in cell-free protein expression, have announced an exciting new partnership aimed at accelerating the discovery and validation of next-generation monoclonal antibodies. This collaboration represents a significant advancement in the field of therapeutic antibody research and promises to reshape the future of biopharmaceutical development.

The Essence of the Collaboration

At the heart of this venture is the combination of mAIbe's innovative, AI-enabled platform for antibody design and optimization with LenioBio's state-of-the-art cell-free expression technology. This fusion of strengths aims to streamline and enhance the traditional design-build-test cycle, thereby significantly boosting the efficiency of the entire process.

LenioBio's ultra-rapid and scalable expression system facilitates the swift production of complex antibodies. This capability ensures that high-quality experimental data can be quickly generated, which in turn feeds directly back into mAIbe’s AI models. This integrated approach is set to expedite several critical processes such as:

• - Accelerating the functional testing of AI-generated antibody candidates: The partnership will allow for a more rapid evaluation of potential candidates derived from mAIbe's AI designs, improving the chances of success in clinical applications.

• - Increasing efficiency and throughput of early validations: The collaboration is designed to enhance the speed at which early-stage antibody candidates are tested and validated, reducing the time from concept to potential therapy.

• - Facilitating faster iterations between computational predictions and experimental results: By bridging the gap between lab outcomes and AI insights, both companies can foster a more dynamic feedback loop, allowing for continual refinement of antibody designs.

Setting a New Standard

Together, mAIbe and LenioBio aim to set a new benchmark in speed, flexibility, and innovation based on data-driven methodologies in therapeutic antibody research. Their joint efforts not only reflect a commitment to pushing the boundaries of biotechnological advances but also signify a crucial step in bridging the gap between laboratory research and practical application in drug development.

About LenioBio

Founded in 2016 and headquartered in Düsseldorf, Germany, LenioBio GmbH is a visionary biotechnology firm that has pioneered cell-free protein expression technology through its ALiCE® platform. This cutting-edge approach allows for the rapid discovery, development, and scalable production of proteins outside of living cells. The company also boasts a robust research and development presence in Aachen, equipped to drive innovation forward in the biopharmaceutical landscape.

For more details, please visit LenioBio's website and connect with them on LinkedIn.

About mAIbe

mAIbe, based in Rome, Italy, focuses on AI-powered monoclonal antibody design. The firm's platform leverages physics-based generative AI and synthetic biology to create precise and cost-effective antibodies targeting viral and bacterial pathogens. By integrating the power of artificial intelligence with biological sciences, mAIbe aims to accelerate the advancement of next-generation immunotherapies that are accessible and effective.

To learn more about their mission, visit mAIbe's website.

As the biopharmaceutical landscape continues to evolve, collaborations like that of mAIbe and LenioBio highlight the importance of integrating technology and innovation to meet the challenges of tomorrow's healthcare needs. Investors and stakeholders in the biotechnology space will undoubtedly be watching this partnership closely, as it unfolds and sets new standards for research and therapeutic applications.